Plasma proteome profiling reveals biomarkers of chemotherapy resistance in patients with advanced colorectal cancer

Abstract

Colorectal cancer (CRC) is one of the most common cancers. Patients with advanced CRC can only rely on chemotherapy to improve outcomes. However, primary drug resistance frequently occurs and is difficult to predict. Changes in plasma protein composition have shown potential in clinical diagnosis. Thus, it is urgent to identify potential protein biomarkers for primary resistance to chemotherapy for patients with CRC. Automatic sample preparation and high-throughput analysis were used to explore potential plasma protein biomarkers. Drug susceptibility testing of circulating tumor cells (CTCs) has been investigated, and the relationship between their values and protein expressions has been discussed. In addition, the differential proteins in different chemotherapy outcomes have been analyzed. Finally, the potential biomarkers have been detected via enzyme-linked immunosorbent assay (ELISA). Plasma proteome of 60 CRC patients were profiled. The correlation between plasma protein levels and the results of drug susceptibility testing of CTCs was performed, and 85 proteins showed a significant positive or negative correlation with chemotherapy resistance. Forty-four CRC patients were then divided into three groups according to their chemotherapy outcomes (objective response, stable disease, and progressive disease), and 37 differential proteins were found to be related to chemotherapy resistance. The overlapping proteins were further investigated in an additional group of 79 patients using ELISA. Protein levels of F5 and PROZ significantly increased in the progressive disease group compared to other outcome groups. Our study indicated that F5 and PROZ proteins could represent potential biomarkers of resistance to chemotherapy in advanced CRC patients.

Keywords

biomarker / chemotherapy resistance / colorectal cancer / plasma proteome

References

[1] Sung H , Ferlay J , Siegel RL , Laversanne M , Soerjomataram I , Jemal A , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021; 71 (3): 209- 49.

[2] Chen W , Zheng R , Baade PD , Zhang S , Zeng H , Bray F , et al. Cancer statistics in China, 2015. CA A Cancer J Clin. 2016; 66 (2): 115- 32.

[3] Engstrand J , Nilsson H , Strömberg C , Jonas E , Freedman J . Colorectal cancer liver metastases — a population-based study on incidence, management and survival. BMC Cancer. 2018; 18 (1): 78.

[4] Maindrault-Goebel F , de Gramont A , Louvet C , André T , Carola E , Mabro M , et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer. 2001; 37 (8): 1000- 5.

[5] de Gramont A , Figer A , Seymour M , Homerin M , Hmissi A , Cassidy J , et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18 (16): 2938- 47.

[6] Van Cutsem E , Rivera F , Berry S , Kretzschmar A , Michael M , DiBartolomeo M , et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009; 20 (11): 1842- 7.

[7] Sun BB , Maranville JC , Peters JE , Stacey D , Staley JR , Blackshaw J , et al. Genomic atlas of the human plasma proteome. Nature. 2018; 558 (7708): 73- 9.

[8] Das V , Kalita J , Pal M . Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 2017; 87: 8- 19.

[9] Qiu B , Guo W , Zhang F , Lv F , Ji Y , Peng Y , et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021; 12 (1): 6770.

[10] Gkountela S , Castro-Giner F , Szczerba BM , Vetter M , Landin J , Scherrer R , et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019; 176 (1-2): 98- 112.e14.

[11] Chen Z , Zhang S , Ma S , Li C , Xu C , Shen Y , et al. Evaluation of the in vitro chemosensitivity and correlation with clinical outcomes in lung cancer using the ATP-TCA. Anti Cancer Agents Med Chem. 2018; 18 (1): 139- 45.

[12] Chen Y , Zhu M , Shen J , He W , Qiu L , Xu R . Chemosensitivity evaluation using circulating tumor cells predicts chemotherapy outcomes in patients with advanced cancer. Clin Lab. 2022; 68 (1).

[13] Geyer PE , Wewer Albrechtsen NJ , Tyanova S , Grassl N , Iepsen EW , Lundgren J , et al. Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol Syst Biol. 2016; 12 (12): 901.

[14] Niu L , Thiele M , Geyer PE , Rasmussen DN , Webel HE , Santos A , et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med. 2022; 28 (6): 1277- 87.

[15] Xu JY , Zhang C , Wang X , Zhai L , Ma Y , Mao Y , et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020; 182 (1): 245- 61.e17.

[16] Ye X , Cui X , Zhang L , Wu Q , Sui X , He A , et al. Combination of automated sample preparation and micro-flow LC-MS for high-throughput plasma proteomics. Clin Proteonomics. 2023; 20 (1): 3.

[17] Liu Y , Liao XW , Qin YZ , Mo XW , Luo SS . Identification of F5 as a prognostic biomarker in patients with gastric cancer. BioMed Res Int. 2020; 2020: 9280841- 913.

[18] Wu X , Zhang Z , Chen X , Xu Y , Yin N , Yang J , et al. A panel of three biomarkers identified by iTRAQ for the early diagnosis of pancreatic cancer. Proteonomics Clin Appl. 2019; 13 (5): e1800195.

[19] Yang H , Geiger M . Cell penetrating SERPINA5 (ProteinC inhibitor, PCI): more questions than answers. Semin Cell Dev Biol. 2017; 62: 187- 93.

[20] Criado García O , Sánchez-Corral P , Rodríguez de Córdoba S . Isoforms of human C4b-binding protein. II. Differential modulation of the C4BPA and C4BPB genes by acute phase cytokines. J Immunol. 1995; 155 (8): 4037- 43.

[21] Huang H , Han Y , Gao J , Feng J , Zhu L , Qu L , et al. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. Med Oncol. 2013; 30 (4): 748.

[22] Ivetic A . A head-to-tail view of L-selectin and its impact on neutrophil behaviour. Cell Tissue Res. 2018; 371 (3): 437- 53.

[23] Zhang T , Yuan K , Wang Y , Xu M , Cai S , Chen C , et al. Identification of candidate biomarkers and prognostic analysis in colorectal cancer liver metastases. Front Oncol. 2021; 11: 652354.

[24] Li N , Wang J , Zhan X . Identification of immune-related gene signatures in lung adenocarcinoma and lung squamous cell carcinoma. Front Immunol. 2021; 12: 752643.

[25] Korniluk A , Kamińska J , Kiszło P , Kemona H , Dymicka-Piekarska V . Lectin adhesion proteins (P-, L- and E-selectins) as biomarkers in colorectal cancer. Biomarkers. 2017; 22 (7): 629- 34.

[26] Shekhar MP . Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets. 2011; 11 (5): 613- 23.

[27] Kufe DW , Major PP . 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem. 1981; 256 (19): 9802- 5.

[28] Johnston PG , Lenz HJ , Leichman CG , Danenberg KD , Allegra CJ , Danenberg PV , et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55 (7): 1407- 12.

[29] Lenz HJ , Hayashi K , Salonga D , Danenberg KD , Danenberg PV , Metzger R , et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998; 4 (5): 1243- 50.

[30] Evrard A , Cuq P , Ciccolini J , Vian L , Cano JP . Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer. 1999; 80 (11): 1726- 33.

[31] Salonga D , Danenberg KD , Johnson M , Metzger R , Groshen S , Tsao-Wei DD , et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000; 6 (4): 1322- 7.

[32] Takebe N , Zhao SC , Ural AU , Johnson MR , Banerjee D , Diasio RB , et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34⁺-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001; 8 (12): 966- 73.

[33] Seger C , Salzmann L . After another decade: LC-MS/MS became routine in clinical diagnostics. Clin Biochem. 2020; 82: 2- 11.

[34] Zacharski LR , Wojtukiewicz M , Costantini V , Ornstein D , Memoli V . Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 1992; 18 (1): 104- 16.

[35] Tas F , Ciftci R , Kilic L , Serilmez M , Karabulut S , Duranyildiz D . Clinical and prognostic significance of coagulation assays in gastric cancer. J Gastrointest Cancer. 2013; 44 (3): 285- 92.

[36] Rezaie AR , Bae JS , Manithody C , Qureshi SH , Yang L . Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem. 2008; 283 (29): 19922- 6.

[37] Vasse M . The protein Z/protein Z-dependent protease inhibitor complex. Systemic or local control of coagulation? Hämostaseologie. 2011; 31 (3): 155- 64.

[38] Wei Z , Yan Y , Carrell RW , Zhou A . Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X. Blood. 2009; 114 (17): 3662- 7.

[39] Therasse P , Arbuck SG , Eisenhauer EA , Wanders J , Kaplan RS , Rubinstein L , et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000; 92 (3): 205- 16.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Quantitative Biology published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.